| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 09/04/2002 | EP1235581A2 Use of ribose to prevent cramping and soreness in muscles |
| 09/04/2002 | EP1235573A2 Combination of riluzole and gabapentin and use thereof as medicine |
| 09/04/2002 | EP0809636B1 Substituted isoxazoles for the treatment of inflammation |
| 09/04/2002 | CN1367787A Water soluble SDZ-RAD esters |
| 09/04/2002 | CN1367775A Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| 09/04/2002 | CN1367693A Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and method of using the same |
| 09/04/2002 | CN1367169A Substituted 6,6-Hetero-dicycloderivative |
| 09/04/2002 | CN1367017A Application of transitional scorpion toxin BmK abT |
| 09/04/2002 | CN1366977A Nano Guloushan dieda preparation medicine and preparation method |
| 09/04/2002 | CN1366958A Nano Dieda Huoxue preparation medicine for curing traumatic injuries and preparation method |
| 09/03/2002 | US6444811 Central nervous system disorders; cardiovascular disorders |
| 09/03/2002 | US6444702 Central nervous system disorders |
| 09/03/2002 | US6444677 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/03/2002 | US6444642 Administering to mammal effective amount of neuregulin polypeptide with p185.sup.erbb2 protein binding activity to stimulate myogenesis of muscle cells |
| 09/03/2002 | CA2237189C 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 08/29/2002 | WO2002066989A2 Diagnostics, assay methods and amelioration of muscular dystrophy symptoms |
| 08/29/2002 | WO2002066650A2 Streptococcus pyogenes polypeptides and corresponding dna fragments |
| 08/29/2002 | WO2002066646A2 Neurotransmission-associated proteins |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066480A2 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 08/29/2002 | WO2002066461A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/29/2002 | WO2002066460A1 Chemical compounds |
| 08/29/2002 | WO2002066422A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 08/29/2002 | WO2002066076A1 A method of treatment and agents useful for same |
| 08/29/2002 | WO2002066050A1 Casoase 3 inhibitors |
| 08/29/2002 | WO2002066049A1 Agents for plasmic change |
| 08/29/2002 | WO2002066030A1 Medicinal compositions comprising diclofenac and ornoprostil |
| 08/29/2002 | WO2002065978A2 Functional agent for decomposing nicotine and method of preparing the same |
| 08/29/2002 | WO2002042273A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001082975A3 Membrane-permeant peptide complexes for medical imaging |
| 08/29/2002 | WO2000066104A9 Ace-2 inhibiting compounds and methods of use thereof |
| 08/29/2002 | WO2000061606A9 Novel human voltage-gated potassium channel |
| 08/29/2002 | WO1999064055A9 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors |
| 08/29/2002 | US20020120948 Modulating gene expression by regulation of cell proliferation; regulated transgene expression in lymphocytes by selective increase in the number of lymphocytes upon exposure to an antigen |
| 08/29/2002 | US20020120149 Substituted hydrazine derivatives |
| 08/29/2002 | US20020120103 17 human secreted proteins |
| 08/29/2002 | US20020119988 Modulators of TNF-alpha signaling |
| 08/29/2002 | US20020119977 Antitumor agents; antiinflammatory agents; analgesics; antipyretic agent |
| 08/29/2002 | US20020119964 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| 08/29/2002 | US20020119961 Bridged piperazine derivatives |
| 08/29/2002 | US20020119164 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 08/29/2002 | US20020119148 ErbB4 antagonists |
| 08/29/2002 | DE10065478C1 Kreatin/Citronensäure-Verbindung, Verfahren zu ihrer Herstellung und Verwendung Creatine / citric acid combination, processes for their preparation and use |
| 08/29/2002 | CA2439193A1 Casoase 3 inhibitors |
| 08/29/2002 | CA2438682A1 Antibodies that bind both bcma and taci |
| 08/29/2002 | CA2438241A1 Medicinal compositions comprising diclofenac and ornoprostil |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2437977A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 08/29/2002 | CA2435177A1 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 08/28/2002 | EP1233983A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233975A1 29 human secreted proteins |
| 08/28/2002 | EP1233963A2 Novel sulfonyl oxazole amines |
| 08/28/2002 | EP1233962A2 Novel heterocyclic compounds and their use as medicines |
| 08/28/2002 | EP1233959A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 08/28/2002 | EP1233951A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 08/28/2002 | EP1233950A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS |
| 08/28/2002 | EP1233945A1 Heterocyclic ketone and thioester compounds and uses |
| 08/28/2002 | EP1233786A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 08/28/2002 | EP1233781A1 Assays and therapies for latent viral infection |
| 08/28/2002 | EP1233777A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233774A1 Urotensin-ii analogs |
| 08/28/2002 | EP1233756A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 08/28/2002 | EP0973731B1 Hydroxamic acid derivatives |
| 08/28/2002 | CN1365759A Nano antalgic medicine 'Zijin' and its preparing process |
| 08/28/2002 | CN1365751A Nano medicine 'Shaolin' for treating rheumatism, bone fracture and injury and its preparing process |
| 08/28/2002 | CN1365714A Nano medicine 'Jiufen' and its preparing process |
| 08/28/2002 | CN1365685A Nano medicine for reating bone fracture and injury and its preparing process |
| 08/28/2002 | CN1365673A Nano medicine 'Fengliaoxing' for treating rheumatism, bone fracture and injury and its preparing process |
| 08/27/2002 | US6441049 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 08/27/2002 | US6441032 Treating systemic lupis and multiple sclerosis |
| 08/27/2002 | US6440995 Quinolin-4-yl derivatives |
| 08/27/2002 | US6440973 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| 08/27/2002 | US6440963 Use of selective COX-2 inhibitors for the treatment of urinary incontinence |
| 08/27/2002 | US6440702 For treatment of motor neuron diseases and muscle degenerative diseases; screening for therapeutic proteins by determining altered electrophoretic binding properties |
| 08/22/2002 | WO2002064795A2 Putative human enzymes |
| 08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
| 08/22/2002 | WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | WO2002064634A2 Human monoclonal antibodies to fc alpha receptor (cd89) |
| 08/22/2002 | WO2002064626A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/22/2002 | WO2002064589A1 Laulimalide derivatives |
| 08/22/2002 | WO2002064576A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 08/22/2002 | WO2002064564A1 Benzo'f!isoindole derivatives with affinity to the ep4 receptor |
| 08/22/2002 | WO2002064135A1 Heterocyclic inhibitors of glycine transporter 2 |
| 08/22/2002 | WO2002064080A2 Matrix metalloproteinase inhibitors |
| 08/22/2002 | WO2002064026A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno |
| 08/22/2002 | WO2001092330A3 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation |
| 08/22/2002 | WO2000020449A9 MODIFIED TGF-β SUPERFAMILY PROTEINS |
| 08/22/2002 | US20020115856 Selective cyclooxygenase-2 (COX-2) inhibitors; for example, 1-(5-Methanesulfonyl-pyridin-2-yl)-7-methoxy-3-trifluoromethyl-4,5-dihydro -1H-benzo(g)indazole |
| 08/22/2002 | US20020115843 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 08/22/2002 | US20020115676 Therapy for andropause using estrogen agonists / antagonists and testosterone |
| 08/22/2002 | US20020115617 Methods for the prevention and / or the treatment of glutamate cytotoxicity |
| 08/22/2002 | US20020115616 Inhibit beta-secretase to reduce beta amyloid peptide concentrations and reduce the amyloid plaques and neuro-fibrillary tangles; Alzheimer's disease; stroke; Down' syndrome; amyotrophic lateral sclerosis; brain disorders |
| 08/22/2002 | US20020115135 Synapse related glycoproteins |
| 08/22/2002 | US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases |
| 08/22/2002 | CA2856986A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 08/22/2002 | CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | CA2438215A1 Putative human enzymes |
| 08/22/2002 | CA2438153A1 Post-partum mammalian placenta, its use and placental stem cells therefrom |